NEWS RELEASES
The information contained in each news release on this page was factually accurate on the date it was issued and posted.
Sutro Appoints Shabbir T. Anik Chief Technical Operations Officer
SOUTH SAN FRANCISCO, June 1, 2016 – Sutro Biopharma today announced the appointment of Dr. Shabbir T. Anik to the newly-created position of chief technical operations officer. Dr. Anik brings over 30 years of experience in pharmaceutical technology, drug development,...
Sutro Expands Senior Leadership Team with Addition of Chief Medical Officer and VP of Translational Pharmacology and Preclinical Development
SOUTH SAN FRANCISCO, Mar. 9, 2016 – Sutro Biopharma today announced the appointment of Arturo Molina, M.D., M.S., FACP as chief medical officer and Mark Lupher, Ph.D., as vice president of translational pharmacology and preclinical development (TP&PD). Both Dr....
Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management
SAN FRANCISCO, Aug. 4, 2015 - Sutro Biopharma today announced that it has appointed Nicki Vasquez, Ph.D., as vice president of alliance and project management. Dr. Vasquez will have a leadership role in the management of Sutro's collaborative partnerships and the...
Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire Agreement
Deal expands Immuno-Oncology Product Discovery and Development Program and Aims to Accelerate Development of Oncology Therapeutics with Compelling Patient Benefit SOUTH SAN FRANCISCO, Oct 23, 2014 – Sutro Biopharma today announced it has entered into a strategic...
Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates
Collaboration and license agreement allows the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, to enhance its access to antibody drug conjugate technologies and to expand its oncology pipeline Sutro’s Xpress CF+™ platforms to be utilized to develop...
Sutro Biopharma to Collaborate with University of California, San Francisco (UCSF), a Recombinant Antibody Network (RAN) Member
Collaboration to Express Antibodies and Antigens based on Sutro’s Technology Platform XpressCF+™ SAN FRANCISCO, Sept. 9, 2014 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug...
Sutro Biopharma to Present at 21st Annual Future Leaders in the Biotech Industry Conference
SAN FRANCISCO, Mar. 24, 2014 - Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it will present at the 21st Annual...
Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to Produce Bispecific Antibodies for the Treatment of Neuroblastoma
SAN FRANCISCO, Jan. 07, 2014 - Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration...
Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
SAN FRANCISCO, Dec. 11, 2013 - Sutro Biopharma today announced that the company has secured $26 million in a Series D financing. The additional financing will fund the expansion of Sutro’s proprietary immuno-oncology product pipeline. Sutro is developing a new...
Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
SAN FRANCISCO, Jan. 31, 2013 - Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, today announced the expansion of its senior management team with the appointment...